Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms

Biomarker Insights
Nadine KutschMartin Schmidt-Hieber

Abstract

Targeting tyrosine kinases represents a highly specific treatment approach for different malignancies. This also includes non-Hodgkin lymphoma since it is well known that these enzymes are frequently involved in the lymphomagenesis. Hereby, tyrosine kinases might either be dysregulated intrinsically or be activated within signal transduction pathways leading to tumor survival and growth. Among others, Bruton's tyrosine kinase (Btk) is of particular interest as a potential therapeutic target. Btk is stimulated by B-cell receptor signaling and activates different transcription factors such as nuclear factor κB. The Btk inhibitor ibrutinib has been approved for the treatment of chronic lymphocytic leukemia and mantle-cell lymphoma recently. Numerous clinical trials evaluating this agent in different combinations (eg, with rituximab or classical chemotherapeutic agents) as a treatment option for aggressive and indolent lymphoma are under way. Here, we summarize the role of tyrosine kinase inhibitors in the treatment of indolent and other non-Hodgkin lymphomas (eg, mantle-cell lymphoma).

References

May 5, 1994·The New England Journal of Medicine·J ParsonnetG D Friedman
Jul 17, 2001·Development Genes and Evolution·R Al-ShawiJ P Simons
Mar 5, 2003·Annual Review of Immunology·Nicholas Chiorazzi, Manlio Ferrarini
Feb 14, 2004·Blood·Freda K Stevenson, Federico Caligaris-Cappio
Apr 24, 2004·The Journal of Biological Chemistry·April N MeyerDaniel J Donoghue
Sep 10, 2005·Blood·Lindsay M MortonMartha S Linet
Dec 3, 2005·Leukemia & Lymphoma·Angela DispenzieriThomas E Witzig
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaohua XinCarla C Heise
Aug 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·Oliver HantschelGiulio Superti-Furga
Aug 21, 2007·Best Practice & Research. Clinical Haematology·Thomas J Kipps
Aug 28, 2007·Nature Biotechnology·Marcus BantscheffGerard Drewes
Jan 20, 2009·Leukemia & Lymphoma·Tanya M WildesRavi Vij
Jun 27, 2009·Blood·Michele Ghielmini, Emanuele Zucca
Jul 3, 2010·Hematological Oncology·Gábor BarnaAndrás Matolcsy
Mar 4, 2011·Blood·Evgeny AronsRobert J Kreitman
Mar 16, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Philip C AmreinJennifer R Brown
May 23, 2012·Expert Opinion on Investigational Drugs·Tadeusz Robak, Ewa Robak
May 24, 2012·Leukemia & Lymphoma·Matthew S Davids, Jennifer R Brown
Aug 31, 2012·The New England Journal of Medicine·Steven P TreonZachary R Hunter
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesJoy Zhu
Sep 20, 2012·Leukemia & Lymphoma·Amir Hossein DaneshmaneshAnders Österborg
Oct 10, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNathan H Fowler
Mar 2, 2013·Nature Reviews. Drug Discovery·Ryan M Young, Louis M Staudt
Mar 5, 2013·American Journal of Hematology·Rakesh BamShmuel Yaccoby
Jun 21, 2013·The New England Journal of Medicine·Michael L WangKristie A Blum
Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien

❮ Previous
Next ❯

Methods Mentioned

BETA
exome sequencing
xenograft

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.